0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Pregabalin for the Treatment of Painful Hand-Foot Skin Reaction Associated With Dabrafenib FREE

Evelyn Lilly, MD1; Matthew Burke, MBA, RN, MSN, APRN-BC2; Harriet Kluger, MD2; Jennifer Choi, MD1,2
[+] Author Affiliations
1Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
2Yale Comprehensive Cancer Center, New Haven, Connecticut
JAMA Dermatol. 2015;151(1):102-103. doi:10.1001/jamadermatol.2014.2455.
Text Size: A A A
Published online

Cutaneous adverse effects are one of the most frequent adverse events (AEs) associated with the use of BRAF inhibitors, reported in 92% to 95% of patients.1 Such dermatologic reactions include maculopapular eruptions, photosensitivity, verrucous keratoses, keratosis pilaris–like eruptions, keratoacanthomas, and melanocytic proliferations.2 Hand-foot skin reaction (HFSR) occurs in 19% to 60% of patients taking BRAF inhibitors1,3 and presents as tender, erythematous patches on the palms and soles.3 Painful hyperkeratotic plaques develop over pressure points. Although 88% of patients have grade 1 symptoms,4 pain can be severe.

The pathogenesis is unknown, but the reaction is dose dependent and so may be due to direct toxic effects of the drug. It has also been postulated that blockage of receptors for vascular endothelial growth factor and platelet-derived growth factor leads to reduced ability to repair vasculature that is subclinically traumatized in the skin. Previously described therapies include emollient creams, keratolytic creams, topical corticosteroids, pyridoxine, COX-2 inhibitors, phototherapy, and decreased chemotherapy dose.

REPORT OF A CASE

A man in his 50s with BRAF V600E–mutated metastatic melanoma treated with twice-daily dabrafenib, 150 mg, developed grade 2 HFSR on his feet after 1 week of treatment, which progressed to grade 3 within a month (grading based on Common Terminology Criteria for Adverse Events, v4.03; http://evs.nci.nih.gov/ftp1/CTCAE/About.html). This was his first treatment for metastatic disease. On the palms and soles bilaterally, he had thick, yellow, hyperkeratotic plaques with erythematous borders most pronounced on the weight-bearing areas, including the metacarpophalangeal joints of the hands, heels, and balls of the feet (Figure). These plaques caused significant pain, interfering with performance of activities of daily living.

Place holder to copy figure label and caption
Figure.
Hand-Foot Skin Reaction to Dabrafenib

Thick, yellow, hyperkeratotic plaques with erythematous borders most pronounced on the weight-bearing areas.

Graphic Jump Location

Minimal improvement was seen after treatment with topical tazarotene, 0.05%, ointment, lidocaine, 5%, ointment, urea, 40%, ointment, and clobetasol, 0.05%, ointment under occlusion. For pain relief, he required use of long-acting oxycodone, 10 mg, every 12 hours, and oxycodone, 5 mg, every 4 hours, which provided mild pain control. He experienced significant improvement after halting treatment with dabrafenib for 2 weeks and subsequently resuming a reduced-dose dabrafenib regimen at 150 mg/d, but he still required narcotics for pain control.

After 2 weeks of low-dose dabrafenib, he started therapy with pregabalin, 50 mg, 3 times daily. Within a week and without any other change in his lifestyle or activity level, the pain in his feet dramatically decreased to the point where he no longer required narcotics and was able to participate in his previous activities. After 45 weeks, he continued to take pregabalin with continuous pain relief in his feet despite unchanged persistent thickened plaques on the soles, for which the topical therapies provided little therapeutic benefit. Of note, the patient had a lifelong history of bipolar disorder and had been taking bupropion, fluoxetine, lamotrigine, and quetiapine throughout this period.

DISCUSSION

Pregabalin is an anticonvulsant widely used as first-line therapy for neuropathic pain secondary to a variety of diseases including diabetes, post-herpetic neuralgia, fibromyalgia, and spinal cord injuries. Pregabalin, like gabapentin, binds to voltage-gated calcium channels and decreases synaptic activity; pregabalin exerts its therapeutic effect at lower doses than does gabapentin, and thus patients experience fewer adverse effects with pregabalin. It has been found to be safe, the most common adverse effects being somnolence and dizziness, which frequently resolve within weeks.5

For the present patient, pregabalin provided more effective symptomatic control than narcotics did for pain related to recalcitrant HFSR. Although he had concurrent bipolar disorder, his psychotropic medication regimen remained stable throughout this period, suggesting that pregabalin helped specifically with his peripheral pain. Although peripheral neuropathy has been associated with acral erythrodysesthesia, agents used to treat neuropathic pain have not been reported for use in acral erythrodysesthesia or HFSR. This case report suggests that pregabalin may be useful as a symptomatic treatment for pain associated with HFSR induced by targeted therapies.

ARTICLE INFORMATION

Corresponding Author: Jennifer Choi, MD, Department of Dermatology, Yale University School of Medicine, 333 Cedar St, Laboratory for Medicine and Pediatrics 5040, New Haven, CT 06510 (Jennifer.choi@yale.edu).

Published Online: September 24, 2014. doi:10.1001/jamadermatol.2014.2455.

Conflict of Interest Disclosures: Dr Choi serves as speaker for Onyx Pharmaceuticals. Mr Burke serves as a speaker for Bristol-Myers-Squibb, Genentech, and Pfizer (a manufacturer of pregabalin). Mr Burke also serves on the advisory board of Pfizer and Merck. No other disclosures are reported.

REFERENCES

Lacouture  ME, Duvic  M, Hauschild  A,  et al.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314-322.
PubMed   |  Link to Article
Belum  VR, Fischer  A, Choi  JN, Lacouture  ME.  Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15(3):249-259.
PubMed   |  Link to Article
Choi  JN.  Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol. 2011;29(6):587-601.
PubMed   |  Link to Article
Boussemart  L, Routier  E, Mateus  C,  et al.  Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691-1697.
PubMed   |  Link to Article
Freynhagen  R, Serpell  M, Emir  B,  et al.  A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2013; doi:10.1111/papr.12146.
PubMed

Figures

Place holder to copy figure label and caption
Figure.
Hand-Foot Skin Reaction to Dabrafenib

Thick, yellow, hyperkeratotic plaques with erythematous borders most pronounced on the weight-bearing areas.

Graphic Jump Location

Tables

References

Lacouture  ME, Duvic  M, Hauschild  A,  et al.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18(3):314-322.
PubMed   |  Link to Article
Belum  VR, Fischer  A, Choi  JN, Lacouture  ME.  Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15(3):249-259.
PubMed   |  Link to Article
Choi  JN.  Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol. 2011;29(6):587-601.
PubMed   |  Link to Article
Boussemart  L, Routier  E, Mateus  C,  et al.  Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691-1697.
PubMed   |  Link to Article
Freynhagen  R, Serpell  M, Emir  B,  et al.  A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2013; doi:10.1111/papr.12146.
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

956 Views
1 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life: Evidence and Experience
Pain and Opioid-Induced Neurotoxicity Contributing to Fatigue

Care at the Close of Life: Evidence and Experience
Treatment of Pain and Opioid-Induced Neurotoxicity